Silence Therapeutics Agrees to $1.3 Billion Merck KGaA Acquisition at 130% Premium

The $20-per-ADS all-cash acquisition agreement follows Phase 2 progress for Divesiran and is expected to close in the first quarter of 2027, subject to shareholder, court and regulatory approvals.

Key Investor Takeaways

• Silence Therapeutics (NASDAQ:SLN) has agreed to be acquired by Merck KGaA, Darmstadt, Germany, in an all-cash transaction valuing its equity at approximately $1.3 billion.
• The $20.00 per ADS acquisition price represents a 130% premium to Silence’s October 16 closing price and an 82% premium to its 30-day volume-weighted average.
• The transaction follows Phase 2 clinical progress for Divesiran, Silence’s investigational siRNA treatment for polycythemia vera.
• Shareholders representing approximately 14% of voting power have agreed to support the acquisition, which has received unanimous board approval.
• Completion is targeted for the first quarter of 2027, with shareholder approval, court sanction and regulatory clearance still required.

Why SLN Stock Is in Focus

Silence Therapeutics (NASDAQ:SLN) has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, in a transaction with an enterprise value of approximately $1.1 billion and an equity value of $1.3 billion.

Under the agreement, Merck will acquire all outstanding ordinary shares of Silence for cash consideration equivalent to $20.00 per American Depositary Share. Each ADS represents three ordinary shares, corresponding to approximately $6.6667 per ordinary share.

The agreed consideration represents a substantial premium to Silence’s recent trading valuation.

The $20.00 offer is 130% above the ADS closing price on October 16, 2026, and 82% above the 30-day volume-weighted average price of $10.99.

Silence’s board unanimously approved the transaction following what the company described as a competitive sale process.

The acquisition will proceed through a UK scheme of arrangement under Part 26 of the Companies Act 2006.

Completion requires approval from Silence shareholders, sanction by the High Court of Justice of England and Wales and satisfaction of customary closing conditions, including regulatory approvals.

Certain shareholders representing approximately 14% of voting power have entered into agreements supporting the transaction.

The companies anticipate closing during the first quarter of 2027.

Why This Matters for Investors

The Merck KGaA acquisition agreement introduces a defined cash consideration for Silence shareholders, shifting the immediate investment focus from the company’s independent clinical development prospects toward transaction completion.

For investors holding Silence Therapeutics shares or ADSs, the agreed $20.00 price establishes the amount payable upon successful closing, rather than a guaranteed payment before the remaining conditions are satisfied.

The substantial acquisition premium also provides a reference point for assessing the transaction relative to Silence’s previous market valuation.

However, the deal remains subject to shareholder, judicial and regulatory approvals. Any difference between the trading price and agreed consideration may reflect factors including completion uncertainty and the time remaining before closing.

The acquisition also changes the prospective development pathway for Silence’s lead clinical asset, Divesiran.

Divesiran is an investigational short interfering RNA therapy targeting TMPRSS6, a gene involved in regulating iron metabolism.

The treatment is being developed for polycythemia vera, a rare blood cancer characterized by excessive red blood cell production.

By targeting TMPRSS6, Divesiran aims to increase hepcidin production and restrict iron availability for red blood cell formation, potentially helping patients maintain hematocrit levels within the recommended treatment range.

The candidate has received FDA Fast Track and Orphan Drug designations for polycythemia vera.

Silence cited potentially best-in-class Phase 2 results as part of the strategic background to the acquisition, although the announcement did not provide detailed clinical efficacy or safety figures.

Merck intends to use its development resources and commercial capabilities to support the program’s progression into Phase 3 testing.

For Silence investors, the proposed transaction would replace direct exposure to future clinical and commercialization outcomes with the agreed cash payment, assuming the acquisition completes.

For Merck, the acquisition would add a clinical-stage siRNA platform and rare-disease development program to its healthcare portfolio.

The transaction follows Merck’s acquisition of SpringWorks Therapeutics in 2025 and reflects its stated strategy of expanding through external innovation and acquisitions in specialized therapeutic areas.

What to Watch Next

The primary catalyst for Silence Therapeutics (NASDAQ:SLN) is the shareholder vote required to approve the proposed acquisition.

Investors will also be monitoring the UK court process, regulatory clearances and any updates to the expected first-quarter 2027 completion timetable.

Although shareholders representing approximately 14% of voting power have committed their support, the transaction still requires the necessary approvals before becoming effective.

Further developments concerning Divesiran’s planned Phase 3 program may also be relevant, particularly as Merck prepares for the potential integration of Silence’s clinical pipeline.

The immediate investment question is whether the acquisition proceeds under the agreed terms and timetable, allowing Silence shareholders and ADS holders to receive the specified cash consideration.

Silence Therapeutics stock price